The future of immune checkpoint therapy
Padmanee Sharma, James Patrick Allison
Science · 2015 · 4,954 citations
No retraction on record in OpenAlex.Check Crossref now
Cite this paper
Sharma, P., & Allison, J. P. (2015). The future of immune checkpoint therapy. Science, 348(6230), 56–61. https://doi.org/10.1126/science.aaa8172
In text: (Sharma & Allison, 2015)
Ask a question about this research
One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.
Abstract
Immune checkpoint therapy, which targets regulatory pathways in T cells to enhance antitumor immune responses, has led to important clinical advances and provided a new weapon against cancer. This therapy has elicited durable clinical responses and, in a fraction of patients, long-term remissions where patients exhibit no clinical signs of cancer for many years. The way forward for this class of novel agents lies in our ability to understand human immune responses in the tumor microenvironment. This will provide valuable information regarding the dynamic nature of the immune response and regulation of additional pathways that will need to be targeted through combination therapies to provide survival benefit for greater numbers of patients.
Related papers
- Integrated analysis of multimodal single-cell data2021
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer2012
- Control of Regulatory T Cell Development by the Transcription Factor Foxp32003
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer2012
- Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins.1986
Metadata from OpenAlex (CC0). Citations are generated from the published record.